Accession Number:



Phase 2 Study of AZD2014, a Dual mTORC1/mTORC1 Inhibitor, for NF2 Patients with Progressive or Symptomatic Meningiomas

Descriptive Note:

Technical Report,15 May 2017,14 May 2018

Corporate Author:

Massachusetts General Hospital Boston United States

Personal Author(s):

Report Date:


Pagination or Media Count:



Meningiomas are common in neurofibromatosis 2 NF2 patients with a cumulative incidence of 80 by 70 years of age. Meningiomas that progress despite surgery and radiation are an important unmet medical need for these patients. To date, no chemotherapy has demonstrated efficacy against NF2-related meningiomas. Our laboratory studies have shown that treatment of primary meningioma cells with AZD2014, a mTORC1mTORC2 inhibitor, leads to decreased cell viabilityproliferation. Thus, we hypothesize that AZD2014 will be effective in treating symptomatic or progressive meningiomas in NF2 patients. In this single arm, non-comparative, phase II trial, 18 patients will be treated with AZD2014 for recurrent or progressive intracranial meningioma. AZD2014 will be administered on a repeating basis at a dose of 125 mg twice daily for two consecutive days out of every seven days 1 cycle 28 days. Treatment will continue until disease progression or intolerable side effects. An MRI of the brain, with and without contrast, will be obtained every 12 weeks to assess for disease response or stability using volumetric measurements. In year 2, 4 additional subjects were enrolled on the study and accrual was completed well in advance of the anticipated 30 months. Data analysis will begin in year 3 of the study.

Subject Categories:

  • Medicine and Medical Research

Distribution Statement: